However, while MAPKAPK3 was downregulated in the DEGs analysis, its expression was upregulated in the validation cohort, and cellular invasion assays suggested its potential involvement in DCIS advancement. Here, MAPKAPK3 is linked to ductal breast carcinoma in situ.